New drug combo aims to tackle tough lymphoma

NCT ID NCT06575686

Terminated Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the safety and effectiveness of combining two drugs, epcoritamab and tazemetostat, for patients with follicular lymphoma that has relapsed or is refractory. The study plans to enroll 33 adults. Epcoritamab helps the immune system attack cancer cells, while tazemetostat blocks enzymes that help cancer grow. The trial is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epcoritamab and tazemetostat
What this could lead to: If it works, this combination could offer a new treatment option for patients with follicular lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is an early phase 2 trial with only 33 participants, currently suspended. The combination may cause side effects or not improve outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GRADE 1 FOLLICULAR LYMPHOMA RECURRENT GRADE 2 FOLLICULAR LYMPHOMA RECURRENT GRADE 3A FOLLICULAR LYMPHOMA REFRACTORY GRADE 1 FOLLICULAR LYMPHOMA REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA

Contacts and locations

Show contact details

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
City of Hope at Irvine Lennar

Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.